Pall Corporation, a specialist in filtration, separation and purification, introduces the mPath bioreactor control system to the biopharmaceutical market
The mPath benchtop bioreactor control system is a first of its kind solution to deliver accurate measurement and control of single use process development scale bioprocesses.
It will support the Allegro XRS 25 bioreactor, with further expansions planned for the mPath portfolio in 2017 and beyond.
Loe Cameron, Director of Analytics and Controls at Pall, said: “Throughout the development of the mPath bioreactor control system, our team was focused on simplifying single-use lab-scale bioprocesses with a functional, integrated user experience.
"The architecture makes plug-and-play connectivity a reality, while providing access to features of Pall bioreactors that other commercial control options do not allow. Additionally, the mPath bioreactor control system has been designed to support characterisation and optimisation and is compliant with cGMP regulations."
An expandable control and data management system includes both bioreactor control towers and an advanced supervisory control and data acquisition (SCADA) software package. The mPath control tower is cleanroom-ready after being IP54 designed and tested, and comes with features such as six mass flow controllers (MFCs) as standard.
Martin Smith, Chief Technology Officer at Pall, said: ”At Pall, we remain driven to advance the biopharmaceutical industry by delivering innovative total solutions to end users. The launch of the mPath bioreactor control system represents the first in our next generation of unifying technologies for a seamless, fully controlled, and value-based user experience."